Cencora Q3 FY25 earnings call COR

The U.S. Healthcare Solutions segment demonstrated outstanding performance, with operating income increasing 29% to $902 million. This was driven by broad-based growth across distribution businesses, strong pharmaceutical utilization trends, and significant contribution from the RCA acquisition. Specialty sales to physician practices and health systems, which are higher-margin businesses, also performed exceptionally well, benefiting from strong volumes and good biosimilar conversion trends.

The International Healthcare Solutions segment experienced a 13% decline in operating income (as-reported) due to continued softness in higher-margin global specialty logistics and consulting businesses, impacted by subdued clinical trial activity. However, management noted sequential growth in the global specialty logistics business from Q2 to Q3, and expects further sequential improvement into Q4, anticipating a return to operating income growth for the segment by the end of the fiscal year due to easier comparisons and improving clinical trial start statistics.

Cencora is focused on four key drivers: digital transformation, talent and culture, productivity, and prioritizing growth-oriented investments. The company highlighted its continued investment in technology and capabilities for customers, the acquisition of RCA, and its investment in OneOncology with a pathway to full ownership. Management emphasized a rigorous discipline in evaluating its portfolio to ensure strategic fit and optimal resource deployment, deprioritizing investments in less aligned areas.

GLP-1 product sales increased $1.4 billion or 19% year-over-year in Q3, contributing to consolidated revenue growth. While GLP-1s remain a significant top-line driver, their growth rate is decelerating compared to prior periods. Management reiterated that GLP-1 products are minimally profitable, so a slowdown in their growth would not materially impact overall earnings guidance, though they expect continued good growth.

The company is actively monitoring the evolving regulatory landscape, including IRA implementation, potential MFN policies, and tariffs. Management stressed the long-term nature of these policy changes and their engagement in Washington D.C. to educate legislators on maintaining patient access to community providers and avoiding unintended consequences like drug shortages from tariff impact^🌐s. They noted no material financial impact from tariffs to date.

The acquisition of Retina Consultants of America (RCA) has been performing strongly and exceeding expectations. Management expressed satisfaction with the cultural fit and the value Cencora brings to RCA physicians and practice leaders for continued growth and patient care. The market's adaptation to MSO investments by distributors was noted, aligning with Cencora's long-standing support for community providers.